Skip to main content
. 2023 Dec 28;17(6):061504. doi: 10.1063/5.0179444

FIG. 2.

FIG. 2.

Disease MPS models developed to evaluate the drug efficacy. (a) Upscaled multi-well arrays of integrated spheroid culture and microfluidic systems have enhanced throughput, while preserving uniform spheroid formation, cytotoxicity assessment, and molecular analysis. Adapted with permission from Liu et al., Anal. Chem. 87(19), 9752–9760 (2015). Copyright 2015 American Chemical Society. (b) MPS models of 3D cell culture and self-assembled microvascular networks to replicate organ-specific tissue architectures and enable drug efficacy testing. Adapted with permission from Paek et al., ACS Nano 13(7), 7627–7643 (2019). Copyright 2019 American Chemical Society. (c) In vitro orthotopic lung MPS chip recapitulating organ microenvironment-specific tumor responses. Reproduced with permission from Hassell et al., Cell Rep. 21(2), 508–516 (2017). Copyright 2017 Elsevier. (d) A tumor-stroma MPS model recapitulating tumor–CAF interaction within the pancreatic tumor microenvironment was facilitated for the assessment of anti-cancer drug efficacy. Adapted with permission from Gampala et al., J. Exp. Clin. Cancer Res. 40(1), 251 (2021). Copyright 2021 Author(s), licensed under a Creative Commons Attribution 4.0 International License. (e) A human microvasculature network within an MPS model was engineered to study the impact of anti-tumor T-cell activity in response to interactions with tumor angiogenesis. Adapted with permission from Kim et al., Nat. Commun. 14(1), 2122 (2023). Copyright 2023 Author(s), licensed under a Creative Commons Attribution 4.0 International License.